Please assess the completion status of the following clinical trial:

Trial Title: Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Arm A: Newly Diagnosed High Grade Glioma Tumor~* Arm B: Recurrent, resectable High Grade Glioma or Ependymoma~* Stable Neurologic Status~* Lanksy/Karnofsky score greater than or equal to 50.~* Adequate Bone Marrow Function (ANC≥ 1000/μL, platelets≥ 100,000/μL transfusion independent, Hemoglobin ≥ 8.0 gm/dL with or without transfusion support)~* Adequate Liver Function (Bilirubin ≤ 2x institutional normal for age, Alanine transaminase (ALT) ≤ 5x institutional normal for age, Aspartate Aminotransferase (AST) ≤ 5x institutional normal for age)~* Adequate Renal Function (Normal creatinine for age and/or glomerular filtration rate ≥ 70 mls/min/1.73 m2)~* Female patients of childbearing potential must have a negative serum or urine pregnancy test~Exclusion Criteria:~* Patients with unresectable disease are not eligible.~* Patients with primary spinal cord tumors are not eligible.~* Patients with metastatic disease are not eligible for Arm A (this does NOT apply to Arm B).~* Patients with a known allergy to any component of the vaccine or any compounds of similar chemical or biologic composition of the vaccine are not eligible.~* Patients with known auto-immune disease are excluded.~* Patients with known immunodeficiency are excluded.~* Patients with a concurrent malignancy are excluded.~* Clinically Significant Concurrent Illness~* Patients receiving any other anticancer or investigational drug~* Patients with uncontrolled seizure disorders~* Patients whose central nervous system (CNS) tumor is considered a secondary malignancy from prior therapies

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Newly Diagnosed High Grade Glioma (HGG) (Type: EXPERIMENTAL): Heat Shock Protein Peptide Complex-96 (HSPPC-96) therapy will be given between 0-28 days after the completion of radiation therapy (XRT) AND no more than 60 days from completion of XRT. Vaccine will be given once weekly for 4 weeks. The 4 weeks (28 days) of vaccine administration will be followed by an observation visit. In patients with sufficient vaccine (on both Arms A and B), a maintenance therapy will be instituted. It will be administered at the same dose the patient was enrolled at and given every 2 weeks until vaccine is exhausted or there is evidence of tumor progression. The first dose of maintenance vaccine should be administered 7 days after completion of the observation visit.
- Recurrent HGG and Ependymoma (Type: EXPERIMENTAL): On Arm B, Heat Shock Protein Peptide Complex-96 (HSPPC-96) will be given as soon as possible after tumor resection post-operative recovery and sufficient time for vaccine preparation (typically 0-28 days post-operatively) AND no more than 60 days post-operatively. Vaccine will be given once weekly for 4 weeks. These 4 weeks (28 days) of vaccines will be followed by an observation visit. In patients with sufficient vaccine, a maintenance therapy will be given. It will be given at the same dose the patient was enrolled at and given every 2 weeks until vaccine is exhausted or there is evidence of tumor progression. The first dose of maintenance vaccine should be given 7 days after completion of the observation visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).